Back to search
FDAFDA · Food and drugs·Recall number D-1471-2022

Timolol Maleate Ophthalmic Solution, USP, 0.5%, 5 x 0.3 mL Single-Dose Vials, Rx Only, Sterile, Manufactured for: Akorn, Inc., Lake Forest, IL 60045. NDC 17478-189-24

Published September 7, 2022 · Recall initiated: August 8, 2022

Summary

FDA records drug Class III recall D-1471-2022, published September 7, 2022 and initiated August 8, 2022. Recalling firm: Akorn, Inc; Status: Ongoing; Reported quantity: 5,226 Cartons (60 vials/carton); Lot: Lot #: 9N72, EXP 09/30/2022. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: Identification of an unknown impurity at the 12-month stability point.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Akorn, Inc
Distributor
Distributed Nationwide in the USA
Lot
Lot #: 9N72, EXP 09/30/2022
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Timolol Maleate Ophthalmic Solution, USP, 0.5%, 5 x 0.3 mL Single-Dose Vials, Rx Only, Sterile, Manufactured for: Akorn, Inc., Lake Forest, IL 60045. NDC 17478-189-24 recalled?

Yes. FDA published recall D-1471-2022 on September 7, 2022. Reported hazard: Failed Impurities/Degradation Specifications: Identification of an unknown impurity at the 12-month stability point.

What should I do if I have this product?

Voluntary: Firm initiated · Letter